Pharmaceutical compositions and methods
This invention relates the use of cortisol blockers (e.g., glucocorticoid receptor [GR] antagonists) for the treating or preventing viral infections, treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.
1. A method of treating a malignancy of the central nervous system in a patient comprising:
selecting a patient in need of treating a malignancy of the central nervous system and administering to the patient at least one active agent selected from the group consisting of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof,
wherein the malignancy of the central nervous system is selected from the group consisting of pancreatic cancer, astrocytomas, oligodendroglioma, glioblastoma, medulloblastoma, brain cancer, neuroblastoma, ganglioneuroblastoma, malignant nerve sheathe tumors, and combinations thereof,
thereby treating said malignancy of the central nervous system.
2. The method of claim 1 wherein the active agent is in a pharmaceutical composition comprising:
a therapeutically effective amount of one or more of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof, and
at least one pharmaceutically acceptable excipient.
3. The method of claim 2 wherein the pharmaceutical composition is in a dosage form selected from the group consisting of a minicapsule, a capsule, a smart capsule, a tablet, an implant, a troche, a lozenge, a minitablet, a temporary or permanent suspension, an injectable, an ovule, a suppository, a wafer, a chewable tablet, a quick or fast dissolving tablet, an effervescent tablet, a buccal or sublingual solid, a granule, a film, a sprinkle, a pellet, a topical formulation, a patch, a bead, a pill, a powder, a triturate, a smart pill, a smart capsule, a platelet, a strip, and a sachet.
4. The method of claim 2 wherein the pharmaceutical composition is in a dosage form for topical application, and at least one pharmaceutically acceptable excipient.
5. The method of claim 2 wherein the pharmaceutical composition is in a dosage form for topical application wherein said formulation is in a form selected from the group consisting of: cream, lotion, gel, oil, ointment, suppository, spray, foam, liniment, aerosol, buccal and sublingual tablet or a transdermal device or patch for absorption through the skin or mucous membranes.
6. A method of treating a malignancy of the central nervous system in a patient comprising:
selecting a patient in need of treating a malignancy of the central nervous system; administering to the patient:
i) a first therapeutic agent selected from the group consisting of temozolomide, busulfan, cisplatin, carboplatin, chlorambucil, cyclophosphamide, ifosfamide, dacarbazine (DTIC), mechlorethamine (nitrogen mustard), melphalan carmustine (BCNU) lomustine (CCNU), 5-FU, capecitabine, methotrexate, gemcitabine, cytarabine (ara-C), fludarabine dactinomycin, daunorubicin, doxorubicin, idarubicin, mitoxantrone, paclitaxel, docetaxel, etoposide (VP-16), vinblastine, vincristine, vinorelbine prednisone, dexamethasone, tamoxifen, fulvestrant, anastrozole, letrozole, megestrol acetate, bicalutamide, flutamide, leuprolide, goserelin, L-asparaginase, and tretinoin, gemcitabine, combinations thereof, and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient;
ii) a second therapeutic agent which is a GCR antagonist selected from the group consisting of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient;
wherein the malignancy of the central nervous system is selected from the group consisting of pancreatic cancer, astrocytomas, oligodendroglioma, glioblastoma, medulloblastoma, brain cancer, neuroblastoma, ganglioneuroblastoma, malignant nerve sheathe tumors, and combinations thereof,
thereby treating said malignancy of the central nervous system.
7. The method of claim 6 wherein the at least one cancer therapeutic agent and the at least a GCR antagonist is in a single dosage form.
8. The method of claim 6 wherein the pharmaceutical composition is in a dosage form selected from the group consisting of a minicapsule, a capsule, a smart capsule, a tablet, an implant, a troche, a lozenge, a minitablet, a temporary or permanent suspension, an injectable, an ovule, a suppository, a wafer, a chewable tablet, a quick or fast dissolving tablet, an effervescent tablet, a buccal or sublingual solid, a granule, a film, a sprinkle, a pellet, a topical formulation, a patch, a bead, a pill, a powder, a triturate, a smart pill, a smart capsule, a platelet, a strip, and a sachet.
9. The method of claim 6 wherein the pharmaceutical composition is in a dosage form for topical application, and at least one pharmaceutically acceptable excipient.
10. The method of claim 6 wherein the pharmaceutical composition is in a dosage form for topical application wherein said formulation is in a form selected from the group consisting of: cram, lotion, gel, oil, ointment, suppository, spray, foam, liniment, aerosol, buccal and sublingual tablet or a transdermal device or patch for absorption through the skin or mucous membranes.
11. A pharmaceutical composition comprising:
i) a first therapeutic agent is at least one cancer therapeutic agent selected from the group consisting of temozolomide, busulfan, cisplatin, carboplatin, chlorambucil, cyclophosphamide, ifosfamide, dacarbazine (DTIC), mechlorethamine (nitrogen mustard), melphalan carmustine (BCNU) lomustine (CCNU), 5-FU, capecitabine, methotrexate, gemcitabine, cytarabine (ara-C), fludarabine dactinomycin, daunorubicin, doxorubicin, idarubicin, mitoxantrone, paclitaxel, docetaxel, etoposide (VP-16), vinblastine, vincristine, vinorelbine prednisone, dexamethasone, tamoxifen, fulvestrant, anastrozole, letrozole, megestrol acetate, bicalutamide, flutamide, leuprolide goserelin, L-asparaginase, and tretinoin, gemcitabine, combinations thereof, and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient;
ii) a second therapeutic agent which is a GCR antagonist selected from the group consisting of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient;
wherein the first and second agents are in multiple separated dosage units or in a single dosage unit of a combination of the therapeutic agents.
12. The pharmaceutical composition of claim 11 wherein the pharmaceutical composition is in a dosage form selected from the group consisting of a minicapsule, a capsule, a smart capsule, a tablet, an implant, a troche, a lozenge, a minitablet, a temporary or permanent suspension, an injectable, an ovule, a suppository, a wafer, a chewable tablet, a quick or fast dissolving tablet, an effervescent tablet, a buccal or sublingual solid, a granule, a film, a sprinkle, a pellet, a topical formulation, a patch, a bead, a pill, a powder, a triturate, a smart pill, a smart capsule, a platelet, a strip, and a sachet.
13. A method of treating a viral condition in a patient comprising:
selecting a patient in need of treating a viral condition;
wherein said viral condition is caused by a member selected from the group consisting of Hepatitis C virus, Bovine Viral Diarrhea virus, Ebola-like viruses, Hepatitis B virus, Mouse mammary tumor virus, Human Immunodeficiency Virus-1 (HIV-1), Varicella-Zoster virus (chicken pox; VZV), Cytomegalovirus (CMV), Human Herpes Virus-6 (HHV-6), Human Herpes Virus-7 (HHV-7), Kaposi's Sarcoma-Associated Herpes virus (or Human Herpes Virus-8; HHV-8), Variola (Small Pox) virus, Vaccinia virus, Cowpox virus, Monkeypox virus, and Coronaviridae and;
administering to the patient at least one active agent selected from the group consisting of PT155, PT156, PT157, PT158, TCY1, combinations thereof, and pharmaceutically acceptable salts thereof, and at least one pharmaceutically acceptable excipient.
14. The method of claim 13 wherein the method comprises treating said viral condition by eliminating acute viral infection, diminishing intensity of a viral infection, diminishing length of a viral infection, speeding time to resolution and healing of a viral infection, speeding time to suppression of a viral infection, increasing likelihood of a viral eradication, and/or diminishing infectivity of a viral infection.
15. The method of claim 13 wherein the method comprises treating said viral condition by preventing an acute viral infection from becoming a chronic active or a latent infection.
16. The method of claim 13 wherein the method comprises treating said viral condition by diminishing intensity of viral reactivation, diminishing length of viral reactivation, speeding time to resolution and healing of viral reactivation, speeding time to suppression of viral reactivation, increasing likelihood of viral eradication, and/or diminishing infectivity of viral reactivation.
17. The method of claim 13 wherein the method comprises treating said viral condition by inactivating latent pro-viral genomes.
18. The method of claim 13 wherein the method comprises treating said viral condition by eliminating acute viral infection, diminishing intensity of viral infection, diminishing length of viral infection, speeding time to resolution and healing of a viral infection, speeding time to suppression of a viral infection, increasing likelihood of a viral eradication, and/or diminishing infectivity of a viral reactivation.
19. The method of claim 13 wherein said virus is selected from the group consisting of Ebola and Marburg virus (Filoviridae); Ross River virus, chikungunya virus, Sindbis virus, eastern equine encephalitis virus (Togaviridae, Alphavirus), vesicular stomatitis virus (Rhabdoviridae, Vesiculovirus), Amapari virus, Pichinde virus, Tacaribe virus, Junin virus, Machupo virus (Arenaviridae, Mammarenavirus, West Nile virus, dengue virus, yellow fever virus (Flaviviridae, Flavivirus); human immunodeficiency virus type 1 (Retroviridae, Lentivirus); Moloney murine leukemia virus (Retroviridae, Gammaretrovirus); influenza A virus (Orthomyxoviridae); respiratory syncytial virus (Paramyxoviridae, Pneumovirinae, Pneumovirus); vaccinia virus (Poxviridae, Chordopoxvirinae, Orthopoxvirus); herpes simplex virus-type 1, herpes simplex virus type 2 (Herpesviridae, Alphaherpesvirinae, Simplexvirus); human cytomegalovirus (Herpesviridae, Betaherpesvirinae, Cytomegalovirus); Autographa californica nucleopolyhedrovirus (Baculoviridae, Alphabaculoviridae) (an insect virus); Semliki Forest, O'nyong-nyong virus, western/Venezuelan equine encephalitis virus, rubella (German measles) virus (Rubivirus); rabies virus, Lagos bat virus, Mokola virus (Rhabdoviridae, Lyssavirus), Guanarito virus, Sabia virus, Lassa virus (Arenaviridae, Mammarenavirus); Zika virus, Japanese encephalitis virus, St. Louis encephalitis virus, tick-borne encephalitis virus, Omsk hemorrhagic fever virus, Kyasanur Forest virus (Flaviviridae, Flavivirus); human hepatitis C virus (Flaviviridae, epacivirus); influenza A/B virus (Orthomyxoviridae, the common “flu” virus); Hendra virus, Nipah virus (Paramyxoviridae, Paramyxovirinae, Henipavirus); measles virus (Paramyxoviridae, Paramyxovirinae, Morbillivirus); variola major (smallpox) virus (Poxviridae, Chordopoxvirinae, Orthopoxvirus); Picornaviridae; human hepatitis B virus (Hepadnaviridae, Orthohepadnavirus); hepatitis delta virus (hepatitis D virus) (unassigned Family, Deltavirus); and human cytomegalovirus (Herpesviridae, Betaherpesvirinae).